EPIGENETICS DRUGS & DIAGNOSTIC TECHNOLOGIES MARKET ANALYSIS (2020-2027) - PowerPoint PPT Presentation

About This Presentation

Title:

EPIGENETICS DRUGS & DIAGNOSTIC TECHNOLOGIES MARKET ANALYSIS (2020-2027)

Description:

Read here the market research report on the “Epigenetics Drugs & Diagnostic Technologies Market" published by CMI Team – PowerPoint PPT presentation

Number of Views:52

Slides: 21

Provided by: kunalbhuta

Category: Other

more less

Transcript and Presenter's Notes

Title: EPIGENETICS DRUGS & DIAGNOSTIC TECHNOLOGIES MARKET ANALYSIS (2020-2027)

1

Coherent Market Insights
Market Research and Business Consulting Services
https//www.coherentmarketinsights.com/
COVID-19 Impact Tracker

2
EPIGENETICS DRUGS DIAGNOSTIC TECHNOLOGIES
MARKET ANALYSIS (2020-2027)

Epigenetics Drugs Diagnostic Technologies
Market, By Type (Epigenetic Drugs (DNMT
Inhibitors (Azacitidine, Decitabine), HDAC
Inhibitors (Vorinostat, Romidepsin)), Epigenetics
Diagnostic Technologies (DNA Methylation, ChIP
Technology)), and By Region (North America, Latin
America, Europe, Asia Pacific, Middle East
Africa) - Size, Share, Outlook, and Opportunity
Analysis, 2020 - 2027

Epigenetics can be defined as the study of
chemical modifications of some specific genes of
an organism. A gene can be altered with change in
the sequence of its DNA or epigenetic
programming. Epigenetic drugs make it possible to
reverse the aberrant gene expression which leads
to various disease states.

4
Statistics

The global epigenetic drugs and diagnostic
technologies market is estimated to account
for US 28,606.6 Mn in terms of value by the end
of 2027.

5
Global Epigenetic Drugs and Diagnostic
Technologies Market Drivers

Increasing prevalence of cancer is expected to
propel growth of the global epigenetic drugs and
diagnostic technologies market over the forecast
period. For instance, according to the American
Cancer Society, in 2019, there will be an
estimated 1,762,450 new cancer cases diagnosed
and 606,880 cancer deaths in the U.S.
Moreover, RD in epigenetic drugs is also
expected to aid in growth of the market. For
instance, the study, Vorinostat in the acute
neuroinflammatory form of X?linked
adrenoleukodystrophy, published in May 2020, in
Annals of Clinical and Translational Neurology,
reported that treatment with certain epigenetic
medicines may help compensate for a deficiency in
the ABCD1 gene in patients with
adrenoleukodystrophy.

6
Statistics

North America held dominant position in the
global epigenetic drugs and diagnostic
technologies market in 2019, accounting
for 40.8 share in terms of value, followed by
Europe and Asia Pacific, respectively.

7
Figure 1 Global Epigenetic Drugs and Diagnostic
Technologies Market Share () Value, By Region,
2019
8
Global Epigenetic Drugs and Diagnostic
Technologies Market Restraints

Longer durations of RD for developing epigenetic
drugs is expected to hinder growth of the market.
It takes a new drug 12 years to go from research
lab to patient, with many thousands of candidates
discarded along the way.
Moreover, lack of evidence regarding the efficacy
of epigenetic therapy in solid tumors is also
expected to limit the market growth.

9
(No Transcript)
10
Global Epigenetic Drugs and Diagnostic
Technologies Market Opportunities

Funding for RD in epigenetics is expected to
offer lucrative growth opportunities for players
in the global epigenetic drugs and diagnostic
technologies market. For instance, in June 2020,
The University of Illinois at Chicago, U.S.,
received US 8.2 million from the National
Institute on Alcohol Abuse and Alcoholism to
continue the Center for Alcohol Research in
Epigenetics and its research on how alcohol
affects genes through epigenetics.

Moreover, development machine-learning algorithms
to aid in epigenetic drug discovery is also
expected to boost the market growth. For
instance, in October 2019, researchers at Sanford
Burnham Prebys Medical Discovery Institute, U.S,
developed a machine-learning algorithm that
gleans information from microscope images in
order to allow high-throughput epigenetic drug
screens.

12
Statistics

The global epigenetic drugs and diagnostic
technologies market was valued at US 6,800.3
Mn in 2019 and is forecast to reach a value
of US 28,606.6 Mn by 2027 at a CAGR of
19.7 between 2020 and 2027.

Figure 2 Global Epigenetic Drugs and Diagnostic
Technologies Market Value (US Mn), 2016 2027

14
Market Trends/Key Takeaways

The market is witnessing RD of novel epigenetic
drugs. For instance, in November 2019,
researchers with the Pasteur Institute and CNRS
(French National Center for Scientific Research),
France, reported identifying epigenetic
inhibiting drugs that can inhibit DNA methylation
and eliminate even the most resistant of the
malaria parasites, Plasmodium falciparum, in the
journal ACS Central Science.
The market is also witnessing entry of new
players. For instance, in September 2019, Omega
Therapeutics, a biotech startup, announced its
entry in RD of medicines based on epigenetics.

15
Global Epigenetic Drugs and Diagnostic
Technologies Market Competitive Landscape

Major players operating in the global epigenetic
drugs and diagnostic technologies market include,
4SC AG, Acetylon Pharmaceuticals, Inc., Astex
Pharmaceuticals Inc., CellCentric Ltd., Celleron
Therapeutics Ltd., Celgene Corporation, Chroma
Therapeutics Ltd., Epigentek Group Inc., Eisai
Co. Ltd., EnVivo Pharmaceuticals Inc., Base
Genomics, and Oryzon Genomics, S.A.

16
Global Epigenetic Drugs and Diagnostic
Technologies Market Key Developments

Major players in the market are focused on
launching new products to expand their product
portfolio. For instance, in July 2020, EpiGentek
launched a series of SARS-CoV-2 research assays
in combatting the ongoing COVID-19 pandemic.
Major players in the market are also focused on
adopting collaboration strategies to expand their
product portfolio. For instance, in June 2020,
Oryzon Genomics, S.A., a clinical-stage
biopharmaceutical company leveraging epigenetics
for RD of new therapies, collaborated with
Institute of Medical and Molecular Genetics
(INGEMM) of the La Paz University Hospital in
Madrid for RD of precision medicine in patients
with Phelan-McDermid Syndrome.

Request Sample Report
Request Customization
Download PDF Brochure
Talk to Analyst
Buy Now
Reference https//www.coherentmarketinsights.com/
market-insight/epigenetics-drugs-and-diagnostic-te
chnologies-market-4026

18
About Us

Coherent Market Insights is a global market
intelligence and consulting organization focused
on assisting our plethora of clients achieve
transformational growth by helping them make
critical business decisions.
What we provide
Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis

19
Contact Us